meningococcal group b vaccine (recombinant, adsorbed)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Trumenba. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Trumenba.

For practical information about using Trumenba, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 02/12/2022

Authorisation details

Product details
Agency product number
Active substance
Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily A; Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily B
International non-proprietary name (INN) or common name
meningococcal group b vaccine (recombinant, adsorbed)
Therapeutic area (MeSH)
Meningitis, Meningococcal
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Boulevard de la Plaine 17
1050 Bruxelles

Product information

23/11/2022 Trumenba - EMEA/H/C/004051 - IB/0043

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Bacterial vaccines

  • Meningococcal vaccines

Therapeutic indication

Trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.

The use of this vaccine should be in accordance with official recommendations.

Assessment history

How useful was this page?

Add your rating
1 rating
3 ratings